Lifevantage Corp LFVN
We take great care to ensure that the data presented and summarized in this overview for Lifevantage Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LFVN
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny864KShares$11.4 Million0.02% of portfolio
-
Capital Management Corp716KShares$9.47 Million2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA489KShares$6.47 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL460KShares$6.08 Million0.07% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT419KShares$5.54 Million0.03% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA308KShares$4.08 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA292KShares$3.86 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX286KShares$3.78 Million0.0% of portfolio
-
Black Rock Inc. New York, NY201KShares$2.66 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny201KShares$2.65 Million0.0% of portfolio
Latest Institutional Activity in LFVN
Top Purchases
Top Sells
About LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.
Insider Transactions at LFVN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 09
2025
|
Garry Paul Mauro Director |
BUY
Open market or private purchase
|
Indirect |
1,549
+0.89%
|
$18,588
$12.25 P/Share
|
May 09
2025
|
Garry Paul Mauro Director |
BUY
Open market or private purchase
|
Direct |
601
+0.69%
|
$7,212
$12.25 P/Share
|
Apr 28
2025
|
Kristen Cunningham Chief Sales Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,659
-3.39%
|
$43,908
$12.14 P/Share
|
Apr 01
2025
|
Julie Boyster Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,976
-3.33%
|
$59,640
$15.79 P/Share
|
Apr 01
2025
|
Julie Boyster Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,668
+2.98%
|
-
|
Apr 01
2025
|
Carl Aure Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,749
-2.04%
|
$41,235
$15.79 P/Share
|
Apr 01
2025
|
Carl Aure Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,401
+1.75%
|
-
|
Apr 01
2025
|
Kristen Cunningham Chief Sales Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,391
-3.06%
|
$50,865
$15.79 P/Share
|
Apr 01
2025
|
Kristen Cunningham Chief Sales Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.63%
|
-
|
Apr 01
2025
|
Alissa Neufeld General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,799
-2.96%
|
$41,985
$15.79 P/Share
|
Apr 01
2025
|
Alissa Neufeld General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+2.74%
|
-
|
Apr 01
2025
|
Steven R Fife President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,089
-3.23%
|
$316,335
$15.79 P/Share
|
Feb 17
2025
|
Julie Boyster Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,890
-2.43%
|
$52,020
$18.56 P/Share
|
Feb 10
2025
|
Michael A Beindorff Director |
SELL
Open market or private sale
|
Direct |
5,850
-11.7%
|
$111,150
$19.54 P/Share
|
Feb 10
2025
|
Cynthia Latham Director |
SELL
Open market or private sale
|
Direct |
4,450
-7.98%
|
$89,000
$20.02 P/Share
|
Feb 10
2025
|
Raymond B Greer Director |
SELL
Open market or private sale
|
Direct |
8,000
-7.46%
|
$160,000
$20.15 P/Share
|
Jan 01
2025
|
Alissa Neufeld General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,157
-3.32%
|
$53,669
$17.53 P/Share
|
Jan 01
2025
|
Alissa Neufeld General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,668
+2.73%
|
-
|
Jan 01
2025
|
Carl Aure Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,269
-2.41%
|
$55,573
$17.53 P/Share
|
Jan 01
2025
|
Carl Aure Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,401
+1.74%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 191K shares |
---|---|
Exercise of conversion of derivative security | 70.4K shares |
Open market or private purchase | 4.82K shares |
Payment of exercise price or tax liability | 171K shares |
---|---|
Open market or private sale | 18.3K shares |